The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review.
Ryaan El-AndariNicholas M FialkaJimmy J H KangSabin J BozsoJayan NagendranJeevan NagendranPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide benefits for patients with heart failure along with a host of positive modulatory effects on the cardiovascular system, including reductions in inflammatory properties, hypertension, and left ventricular volume load. Given the clear benefit provided by SGLT2i to patients with cardiovascular disease and a host of positive properties that are expected to be protective for patients with ischemic heart disease, future investigation into the relationship between SGLT2i and outcomes for patients undergoing revascularization is imperative.
Keyphrases
- cardiovascular disease
- patients undergoing
- left ventricular
- percutaneous coronary intervention
- coronary artery bypass grafting
- coronary artery disease
- blood pressure
- aortic stenosis
- coronary artery
- acute myocardial infarction
- heart failure
- oxidative stress
- current status
- hypertrophic cardiomyopathy
- mitral valve
- acute coronary syndrome
- metabolic syndrome
- cardiac resynchronization therapy
- transcatheter aortic valve replacement
- atrial fibrillation
- ejection fraction
- insulin resistance
- cardiovascular risk factors